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The D13S171 Marker, Misannotated to BRCA2, Links
the AS3 Gene to Various Cancers
To the Editor:
Our comment concerns a recent letter to the Journal, in
which de los Rios et al. (2001) reported the complete
lack of BRCA2 mutations in 23 families with breast
cancer and found only a single BRCA2 mutation in 66
Polish families with breast and ovarian cancer (Gorski
et al. 2000). These data rule out BRCA2 from a portion
of familial breast cancers, and they are reminiscent of
data on the sporadic form of the disease, in which
BRCA2 mutations are also absent (Miki et al. 1996;
Teng et al. 1996; Brody et al. 1998).
A correlation of BRCA2 mutations and deletions with
breast cancer is well established in a minority of families
with breast cancer. At the biochemical level, BRCA2 is
believed to function in DNA damage survey. The notion
that BRCA2 is a tumor suppressor, however, is contra-
dicted by its high expression in proliferating cells
(Vaughn et al. 1996), its expression in sporadic breast
cancer (Bieche et al. 1999), its positive correlation with
a high mitotic index (Bieche et al. 1999), and the lack
of mammary-gland cancer phenotype in BRCA2-trun-
cated knockout mice (Connor et al. 1997). Moreover,
in breast cancers with losses in the 13q12.3 region, the
expression of the intact BRCA2 transcript (Bieche et al.
1999) and of the BRCA2 protein (Edwards et al. 1998)
strongly suggest that the deletions targeted another gene
in the area (a “cryptic” suppressor), a conclusion shared
by others in the field.
Our search for genes involved in the repression of cell
proliferation revealed a marker misannotation in the
BRCA2 area. Our analysis shows that the correct an-
notation, in fact, identifies a new proliferation-arrest
gene, known as “androgen-shutoff gene 3” (AS3), in this
region and implicates it in cancer. Correct annotation
also changes the interpretation of BRCA2 allelic imbal-
ance data, which may ultimately explain the negative
results reported by de los Rios et al. and others.
We mapped AS3 on chromosome 13 and found in-
consistencies in the positions of critical markers in the
databases of microsatellite markers (Cooperative Hu-
man Linkage Center, version 4), STS data (Unified Data
Base, Integrated Chromosome 13 Map), radiation hy-
brid data (GeneMap99), and other sources. The nucleo-
tide sequence and the individual contigs of the 13q12-
13 area are now available through the Human Genome
Project (Homo sapiens 13q12-q13 contig, 1,416,908 bp,
accession number NT_000625). This allowed us to es-
tablish the precise nucleotide sequence–based positions,
not only for AS3 (accession number NM_015928 or
U95825) but for other markers and genes as well (see
fig. 1)—for instance, the D13S260 (S260), D13S171
(S171), and D13S267 (S267) markers that have been the
main focus of clinical studies. The S267 marker is telo-
meric to the sequence depicted in figure 1.
The assignment of the S171 marker (accession number
Z17151) is of particular importance, because it has been
annotated to BRCA2 and widely used as an intragenic
marker of BRCA2 (accession number XM_007138). Al-
lelic imbalance data directly linked the marker to a sup-
pressor gene. Increased proliferation rates in invasive
ductal breast carcinoma (Beckmann et al. 1996) and
lung carcinoma (Gorgoulis et al. 2000), deletions in
sporadic breast cancer (Cleton-Jansen et al. 1995), un-
favorable prognosis in prostate cancer (Edwards et al.
1998), and lymph node metastases in esophageal car-
cinoma (Harada et al. 1999) were positively correlated
with losses in the S171 marker. In a study of hepato-
cellular carcinoma, the smallest common deleted region
(SCDR1) was also the S171 marker (Lin et al. 1999).
These losses point to a critical gene in the S171 position,
as documented in the studies of patients with cancer
mentioned above.
Our sequence-based mapping unambiguously dem-
onstrated, however, that this gene is not BRCA2. Our
data show that the S171 marker is not intragenic to
BRCA2 (see fig. 1) and that losses in the marker cannot
be directly interpreted as BRCA2 losses. The new gene,
AS3, which is located in the S171 position, has recently
been identified in prostate cancer cells undergoing an-
drogen-induced proliferative arrest and shows the ex-
pression pattern of a negative regulator (Geck et al.
1997). Our sequence analysis identified the S171 micro-
satellite repeat as part of intron 10 of the genomic region
of AS3. The 34 exons in a 200-kb area around the S171
marker code for a protein of ∼1,400 residues with var-
ious consensus domains (Geck et al. 1999). The 165-kD
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Figure 1 Map positions of markers and genes on the nucleotide sequence of the 13q12-13 contig. Boxes indicate markers that have been
the main focus of clinical studies. Top, Microsatellite markers. Markers are shown with numbers that indicate the positions of the first nucleotides
of the amplicons. The scale refers to that of the 13q12-13 contig. The hatched bar represents the homozygous deletion in a pancreatic
adenocarcinoma that partially removed the AS3 coding region. The left border of the deletion is centromeric to DPC2 (at ∼450,000 position),
and its right border is telomeric to DPC1 (at ∼780,000–830,000 positions) (Schutte et al. 1995). Middle, the identified coding sequences in the
area. Sequences are shown on the same scale as in the top panel. The arrowheads indicate the directions of transcription. The names in
parentheses indicate alternative names or alternative transcripts. Bottom, the nucleotide sequence of the 13q12-13 contig in 0.1-Mb units.
AS3 protein is localized in the cell nucleus. Expression
of the sense and antisense AS3 sequence from a tetra-
cycline-regulated retroviral construct showed that AS3
is a powerful negative regulator of cell proliferation
(Geck et al. 2000). Recently, clinical studies have directly
implicated AS3 in the development of esophageal cancer,
through polymorphic variations and loss of heterozy-
gosity that linked AS3 to lymph node metastases (Har-
ada et al. 2001).
These data and the corrected map positions clearly
indicate that (a) the exact location of the S171 marker
is at the center of the 200-kb AS3 gene and is not
intragenic to BRCA2, (b) the S171 microsatellite insta-
bility data link AS3 to a variety of cancers, (c) the AS3
gene product is a powerful negative regulator of cell
proliferation, and (d) clinical data directly implicate AS3
in cancer. Unfortunately, on the basis of the public data-
base annotations, the recent literature consistently as-
signs the S171 marker to BRCA2 (Edwards et al. 1998;
Lin et al. 1999; Gorgoulis et al. 2000). In the light of
our analysis, it is highly misleading to assign the S171
allelic instability data unconditionally and exclusively to
BRCA2. Our results correct this misperception and re-
veal that AS3 is the real cognate gene of the marker, a
prime candidate for a role in the negative regulation of
cell proliferation.
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Department of Anatomy and Cell Biology,
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The Autism Genetic Resource Exchange: A Resource
for the Study of Autism and Related Neuropsychiatric
Conditions
To the Editor:
In this letter, we describe the Autism Genetic Resource
Exchange (AGRE), a resource for the study of autism
and pervasive developmental disorder (PDD). Autism
presents within the first 3 years of life, is characterized
by qualitative impairments in communication and social
interaction—in the presence of restricted repetitive and
stereotyped patterns of behavior, interests, and activi-
ties—and is part of a spectrum of disorders that includes
Asperger syndrome and PDD (American Psychiatric As-
sociation 1994). Estimates of the prevalence of autism
in the general population ranges from 0.04% to 10.l%
(Bryson et al. 1988; Gillberg et al. 1991). Twin and
family studies have demonstrated that the genetic con-
tribution to autism and PDD is significant, with an MZ-
twin concordance of 60%–90% and a 45- to 150-fold
increase in risk to siblings (Ritvo et al. 1989; Jorde et
al. 1990; Bailey et al. 1995). Thus, molecular genetic
studies of autism-spectrum disorders are likely to con-
tribute significantly to our understanding of this con-
dition, as the recent results of several independent ge-
nome scans suggest (International Molecular Genetic
Study of Autism Consortium 1998; Barrett et al. 1999;
Philippe et al. 1999; Risch et al. 1999).
AGRE has been developed as a joint effort of the Cure
Autism Now (CAN) Foundation and the Human Bio-
logical Data Interchange (HBDI), to facilitate collabo-
rative genetic research into the etiology of autism and
PDD and to make biomaterials from well-characterized
families with autism widely available to the scientific
community, so as to accelerate research. Since genetic
studies of complex neuropsychiatric conditions are lim-
ited by the large sample sizes needed to attain adequate
power (Lander and Kruglyak 1995; Risch and Meri-
kangas 1996), the consolidation of large numbers of
families into one collection that is made available to
researchers at a fraction of the cost originally incurred
